|
Collaborative arrangements (Textuals) (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2011
|
Sep. 30, 2011
|
Jun. 30, 2011
|
Mar. 31, 2011
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
||||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||
| ENBREL sales | $ 4,337 | $ 4,201 | $ 4,200 | $ 3,901 | $ 3,907 | $ 3,877 | [1] | $ 3,893 | $ 3,618 | $ 16,639 | $ 15,295 | $ 14,660 | ||
|
Collaborative Arrangement With Pfizer Inc [Member]
|
||||||||||||||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||
| Period required to pay percentage of net sales, after expiration of agreement in years | 3 years | |||||||||||||
| Maximum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013 | 12.00% | 12.00% | ||||||||||||
| Minimum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013 | 10.00% | 10.00% | ||||||||||||
| ENBREL sales | 4,200 | 3,700 | 3,500 | |||||||||||
|
Collaborative Arrangement With Pfizer Inc [Member] | Selling General and Administrative [Member]
|
||||||||||||||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||
| Profit share expenses | 1,495 | 1,288 | 1,184 | |||||||||||
| Cost recoveries | $ 35 | $ 84 | $ 87 | |||||||||||
|
||||||||||||||